INDEX

I. INTRODUCTION 1

1. CANCER 1

1.1 CANCER AND THE IMMUNE SYSTEM 2

2. LUNG CANCER 3

2.1 EPIDEMIOLOGY AND ETHIOLOGY 3

2.2 DIAGNOSIS AND CLASSIFICATION 4

2.2.1 HISTOLOGICAL CLASSIFICATION 6

2.2.2 MOLECULAR CLASSIFICATION 7

2.3 TREATMENT 7

3. IMMUNOTHERAPY 8

3.1 BASIS OF IMMUNOTHERAPY 8

3.2 TYPES OF IMMUNOTHERAPIES 9

3.3 IMMUNE CHECKPOINT BLOCKADE IN ADVANCED NSCLC 11

4. TISSUE BIOMARKERS FOR IMMUNOTHERAPY 13

4.1 APPROVED BIOMARKERS 13

4.1.1 PD-L1 13

4.1.2 TUMOUR MUTATIONAL BURDEN 14

4.1.3 MICROSATELLITE INSTABILITY 15

4.2 TISSUE BIOMARKERS UNDER RESEARCH 15

5. NON-INVASIVE BIOMARKERS FOR IMMUNOTHERAPY 16

5.1 NON-INVASIVE PD-L1 17

5.2 BLOOD TUMOUR MUTATIONAL BURDEN 18

5.3 CIRCULATING-TUMOUR DNA 18

5.4 HAEMATOLOGIC AND IMMUNOLOGIC PARAMETERS 18

5.5 IMMUNE-RELATED GENES 21

5.6 TCR REPERTOIRE 27

5.7 HUMAN LEUKOCYTE ANTIGEN 29

5.8 IMMUNOGRAM 30

II. OBJECTIVES 33

III. MATERIALS AND METHODS 37

1. PATIENTS 39

2. SAMPLE COLLECTION 39

3. NUCLEIC ACID ISOLATION FROM PBMCS 40

3.1 RNA ISOLATION 40

3.2 DNA ISOLATION 40

3.3 NUCLEIC ACID QUANTIFICATION AND QUALIFICATION 41

3.3.1 NUCLEIC ACID QUANTIFICATION 41

3.3.2 NUCLEIC ACID QUALIFICATION 41

4. IMMUNE-RELATED GENE EXPRESSION ANALYSIS 42

4.1 REVERSE TRANSCRIPTION 42

4.2 REAL-TIME QUANTITATIVE PCR 42

4.3 GENE EXPRESSION RELATIVE QUANTIFICATION 43

5. TCR REPERTOIRE CHARACTERIZATION 44

5.1 LIBRARY PREPARATION 45

5.1.1 LIBRARY CONSTRUCTION 45

5.1.2 LIBRARY PURIFICATION 46

5.1.3 LIBRARY QUANTIFICATION 47

5.2 DATA ANALYSIS 47

6. HLA GENOTYPING 48

6.1 LIBRARY PREPARATION 49

6.1.1 LIBRARY CONSTRUCTION 49

6.1.2 LIBRARY PURIFICATION, INDEXING AND POOLING 50

6.1.3 LIBRARY QUANTIFICATION AND SEQUENCING 51

6.2 DATA ANALYSIS 51

7. BIOSTATISTICS 52

7.1 DATA COLLECTION AND CURATION 52

7.2 STATISTICAL ANALYSIS 53

IV. RESULTS AND DISCUSSION 55

1. PATIENT COHORT DESCRIPTION 57

2. ANALYTICAL VARIABLES IN NSCLC PATIENTS *VERSUS* CONTROLS 59

2.1 IMMUNE-RELATED GENE EXPRESSION 59

2.2 TCR REPERTOIRE 61

3. CORRELATIONS BETWEEN CLINICOPATHOLOGICAL AND ANALYTICAL VARIABLES 65

3.1 HAEMATOLOGIC AND IMMUNOLOGIC PARAMETERS 65

3.2 IMMUNE-RELATED GENE EXPRESSION 66

3.3 TCR REPERTOIRE 67

3.4 HLA GENOTYPE 68

4. BIOMARKERS FOR ANTI-PD1 MONOTHERAPY 69

4.1 PATIENT DEMOGRAPHIC AND CLINICOPATHOLOGICAL CHARACTERISTICS 69

4.1.1 DURABLE CLINICAL BENEFIT 69

4.1.2 PROGNOSIS 70

4.2 HAEMATOLOGIC AND IMMUNOLOGIC PARAMETERS 71

4.2.1 DURABLE CLINICAL BENEFIT 71

4.2.2 PROGNOSIS 74

4.2.3 DYNAMICS 77

4.3 IMMUNE-RELATED GENE EXPRESSION 78

4.3.1 DURABLE CLINICAL BENEFIT 78

4.3.2 PROGNOSIS 80

4.3.3 DYNAMICS 83

4.4 TCR REPERTOIRE 87

TCR REPERTOIRE METRICS 87

4.4.1 DURABLE CLINICAL BENEFIT – TCR METRICS 87

4.4.2 PROGNOSIS – TCR METRICS 88
4.4.3 DYNAMICS – TCR METRICS 89
TCR REPERTOIRE: TRB V-J GENE FREQUENCIES 93
4.4.4 DURABLE CLINICAL BENEFIT – TRB V-J GENES 93
4.4.5 PROGNOSIS – TRB V-J GENES 96
4.4.6 DYNAMICS – TRB V-J GENES 98
4.5 HLA GENOTYPE 101
4.5.1 DURABLE CLINICAL BENEFIT 101
4.5.2 PROGNOSIS 102
5. BIOMARKERS FOR ANTI-PD1+CT 106
5.1 CLINICOPATHOLOGICAL CHARACTERISTICS 106
5.1.1 DURABLE CLINICAL BENEFIT 106
5.1.2 PROGNOSIS 106
5.2 HAEMATOLOGIC AND IMMUNOLOGIC PARAMETERS 107
5.2.1 DURABLE CLINICAL BENEFIT 107
5.2.2 PROGNOSIS 109
5.2.3 DYNAMICS 112
5.3 IMMUNE-RELATED GENE EXPRESSION 115
5.3.1 DURABLE CLINICAL BENEFIT 115
5.3.2 PROGNOSIS 117
5.3.3 DYNAMICS 119
5.4 TCR REPERTOIRE 123
TCR REPERTOIRE METRICS 123
5.4.1 DURABLE CLINICAL BENEFIT – TCR METRICS 123
5.4.2 PROGNOSIS – TCR METRICS 123
5.4.3 DYNAMICS – TCR METRICS 124
TCR REPERTOIRE: TRB V-J GENE FREQUENCIES 128
5.4.4 DURABLE CLINICAL BENEFIT – TRB V-J GENES 129

5.4.5 PROGNOSIS - TRB V-J GENES 130
5.4.6 DYNAMICS - TRB V-J GENES 133
5.5 HLA GENOTYPE 135
5.5.1 DURABLE CLINICAL BENEFIT 135
5.5.2 PROGNOSIS 137
6. DIFFERENCES ACROSS TREATMENT SCHEMES 140
6.1 HAEMATOLOGIC AND IMMUNOLOGIC PARAMETERS 140
6.2 IMMUNE-RELATED GENE EXPRESSION 143
6.3 TCR REPERTOIRE 146
6.4 HLA GENOTYPES 148
7. NON-INVASIVE IMMUNOGRAM 150
7.1 BASELINE IMMUNOGRAM 150
7.1.1 IMMUNOGRAM FOR ANTI-PD1 MONOTHERAPY 150
7.1.2 IMMUNOGRAM FOR ANTI-PD1+CT 152
7.2 DYNAMIC IMMUNOGRAM 152
7.2.1 DYNAMIC IMMUNOGRAM FOR ANTI-PD1 MONOTHERAPY 153
7.2.2 DYNAMIC IMMUNOGRAM FOR ANTI-PD1+CT 154
8. INTEGRATION OF RESULTS 157
V. CONCLUSIONS 161
VI. REFERENCES 165
VII. APPENDICES 223
1. SUPPLEMENTARY TABLES 225
2. APPROVAL FROM THE INSTITUTIONAL ETHICAL AND SCIENTIFIC REVIEW BOARD 242
3. PATIENT INFORMED CONSENT 244
4. FUNDING 250
5. CONGRESS COMMUNICATIONS 251
6. PUBLICATIONS 252